Owlstone Medical Ltd

Life Sciences

Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.

  • Sector Life Sciences
  • Moved in 2015
  • Staff 45

Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in health care costs.

The company’s microchip FAIMS (Field Asymmetric Ion Mobility Spectrometer) sensor is a platform technology that can be programmed in software to detect targeted biomarkers of disease in breath (and other bodily fluids). FAIMS can be used in clinical diagnostics and precision medicine with application in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and where more lives can be saved.

Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by therapeutic response. The company also sells R&D tools and services to academic, clinical and pharma partners who want to develop breath based diagnostics for their own applications.

Visit website

Owlstone Medical discoveries and awards

2013 2010
  • 2013

    Excellence in Technology Transfer award

    With Dr. Alex Shvartsburg and Dr. Keqi Tang, Owlstone won this award for the potential of the techno

  • 2011

    Distinguished Award

    The Distinguished Award is worth $120k and will help in our efforts to produce a fast, accurate and

  • 2010

    Creation of the breath analyser for disease

    Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit.

  • 2010

    Royal Academy of Engineering

    Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit.

Contact us

Thank you for your enquiry!
We'll be in touch soon.

We couldn't send your message.
Please review the fields then try again